Analysts Set MiMedx Group, Inc. (NASDAQ:MDXG) Price Target at $12.00

Shares of MiMedx Group, Inc. (NASDAQ:MDXG) have been given a consensus rating of “Buy” by the five brokerages that are currently covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $12.00.

Several equities analysts have commented on MDXG shares. Cantor Fitzgerald started coverage on MiMedx Group in a research report on Tuesday, July 2nd. They issued an “overweight” rating and a $11.00 target price for the company. StockNews.com upgraded MiMedx Group from a “buy” rating to a “strong-buy” rating in a research report on Thursday. Finally, HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of MiMedx Group in a research report on Wednesday, May 1st.

MiMedx Group Price Performance

Shares of MDXG stock opened at $7.13 on Wednesday. The company has a quick ratio of 2.71, a current ratio of 3.29 and a debt-to-equity ratio of 0.12. MiMedx Group has a twelve month low of $5.57 and a twelve month high of $9.27. The company has a market cap of $1.05 billion, a P/E ratio of 16.20 and a beta of 1.99. The business has a fifty day simple moving average of $7.19 and a 200 day simple moving average of $7.51.

MiMedx Group (NASDAQ:MDXG) last issued its earnings results on Tuesday, April 30th. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.03. The business had revenue of $84.71 million during the quarter, compared to analysts’ expectations of $79.36 million. MiMedx Group had a return on equity of 39.42% and a net margin of 18.63%. On average, sell-side analysts forecast that MiMedx Group will post 0.32 EPS for the current fiscal year.

Hedge Funds Weigh In On MiMedx Group

A number of hedge funds have recently made changes to their positions in MDXG. AJOVista LLC bought a new position in shares of MiMedx Group during the fourth quarter worth about $25,000. Headlands Technologies LLC bought a new stake in MiMedx Group in the first quarter worth approximately $27,000. Entropy Technologies LP bought a new stake in MiMedx Group in the first quarter worth approximately $99,000. KMG Fiduciary Partners LLC bought a new stake in MiMedx Group in the fourth quarter worth approximately $105,000. Finally, Loudon Investment Management LLC bought a new stake in MiMedx Group in the fourth quarter worth approximately $105,000. 79.15% of the stock is currently owned by institutional investors.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.